Compare Stocks: CAPR, ANNX, KURA, and DBVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$5.29 +0.6%	$5.35	$2.03 ▼ $7.18	$1.00B	1.18	2.51 million shs	2.99 million shs
CAPR Capricor Therapeutics	$6.65 +58.0%	$18.18	$2.96 ▼ $40.37	$385.11M	0.54	7.00 million shs	65.95 million shs
DBVT DBV Technologies	$14.02 -0.1%	$15.21	$8.70 ▼ $26.18	$830.22M	-0.93	409,482 shs	128,541 shs
KURA Kura Oncology	$10.86 +7.6%	$10.22	$6.95 ▼ $12.49	$964.09M	0.38	1.29 million shs	1.89 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-2.22%	-10.19%	+1.54%	+103.46%
CAPR Capricor Therapeutics	0.00%	+62.59%	-65.22%	-76.90%	-19.88%
DBVT DBV Technologies	0.00%	+4.01%	-5.65%	-28.65%	+41.47%
KURA Kura Oncology	0.00%	+13.48%	-0.28%	+17.79%	+67.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$5.29 +0.6%	$5.35	$2.03 ▼ $7.18	$1.00B	1.18	2.51 million shs	2.99 million shs
CAPR Capricor Therapeutics	$6.65 +58.0%	$18.18	$2.96 ▼ $40.37	$385.11M	0.54	7.00 million shs	65.95 million shs
DBVT DBV Technologies	$14.02 -0.1%	$15.21	$8.70 ▼ $26.18	$830.22M	-0.93	409,482 shs	128,541 shs
KURA Kura Oncology	$10.86 +7.6%	$10.22	$6.95 ▼ $12.49	$964.09M	0.38	1.29 million shs	1.89 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-2.22%	-10.19%	+1.54%	+103.46%
CAPR Capricor Therapeutics	0.00%	+62.59%	-65.22%	-76.90%	-19.88%
DBVT DBV Technologies	0.00%	+4.01%	-5.65%	-28.65%	+41.47%
KURA Kura Oncology	0.00%	+13.48%	-0.28%	+17.79%	+67.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.30	Hold	$15.33	189.86% Upside
CAPR Capricor Therapeutics	2.00	Hold	$29.15	338.35% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	245.93% Upside
KURA Kura Oncology	2.69	Moderate Buy	$25.62	135.87% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ANNX, KURA, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.50
7/30/2026	CAPR Capricor Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/28/2026	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$7.00
7/28/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/27/2026	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$0.98 per share	N/A
CAPR Capricor Therapeutics	$22.27M	17.29	N/A	N/A	$5.53 per share	1.20
DBVT DBV Technologies	$5.64M	147.21	N/A	N/A	$2.71 per share	5.17
KURA Kura Oncology	$67.48M	14.29	N/A	N/A	$0.55 per share	19.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	N/A
CAPR Capricor Therapeutics	-$105.04M	-$2.32	N/A	N/A	N/A	N/A	-58.09%	-48.01%	N/A
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)

Latest CAPR, ANNX, KURA, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
7/16/2026	Q2 2026	DBVT DBV Technologies	-$0.12	-$0.60	-$0.48	-$0.60	$0.90 million	$0.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	6.35
CAPR Capricor Therapeutics	N/A	8.42	8.42
DBVT DBV Technologies	N/A	3.72	3.72
KURA Kura Oncology	0.12	4.73	6.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
CAPR Capricor Therapeutics	21.68%
DBVT DBV Technologies	71.74%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
CAPR Capricor Therapeutics	9.20%
DBVT DBV Technologies	1.06%
KURA Kura Oncology	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
CAPR Capricor Therapeutics	101	57.91 million	52.58 million	Optionable
DBVT DBV Technologies	80	59.22 million	58.59 million	Optionable
KURA Kura Oncology	130	88.77 million	82.03 million	Optionable

CAPR, ANNX, KURA, and DBVT Headlines

Recent News About These Companies

FY2029 EPS Estimates for Kura Oncology Decreased by Analyst

2 hours ago | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% After Analyst Upgrade

3 hours ago | americanbankingnews.com

Kura Oncology (KURA) Receives a Buy from Bank of America Securities

August 15 at 3:50 PM | theglobeandmail.com

Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, Wedbush Analyst Says

August 15 at 4:07 AM | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up on Better-Than-Expected Earnings

August 15 at 1:21 AM | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade

August 14 at 2:39 PM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Kura Oncology (KURA) and Inovio Pharmaceuticals (INO)

August 14 at 12:37 PM | theglobeandmail.com

Kura Oncology (NASDAQ:KURA): What Does the Latest Update Mean for Clinical Evidence?

August 14 at 12:37 PM | kalkinemedia.comK

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

August 14 at 8:56 AM | marketbeat.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

August 13 at 10:19 AM | marketbeat.com

Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

August 13 at 9:23 AM | marketbeat.com

Kura Oncology, Inc.: Kura Oncology Reports Second Quarter 2026 Financial Results

August 13 at 8:13 AM | finanznachrichten.de

Kura outlines $90M-$110M 2027 collaboration revenue while targeting 2028 KOMET-017 topline results

August 13 at 8:13 AM | seekingalpha.com

Kura Oncology, Inc. Q2 2026 Earnings Call Summary

August 13 at 8:13 AM | finance.yahoo.com

Kura Oncology: Q2 Earnings Snapshot

August 12, 2026 | sfgate.com

Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

Kura Oncology Q2 Earnings Call Highlights

August 12, 2026 | marketbeat.com

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2026 | zacks.com

Kura Oncology (NASDAQ:KURA) Issues Earnings Results

August 12, 2026 | marketbeat.com

Kura Oncology Reports Second Quarter 2026 Financial Results

August 12, 2026 | globenewswire.com

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

August 10, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CAPR, ANNX, KURA, and DBVT Company Descriptions

Annexon NASDAQ:ANNX

$5.29 +0.03 (+0.57%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.50 +0.21 (+3.97%)

As of 08/14/2026 07:56 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Capricor Therapeutics NASDAQ:CAPR

$6.65 +2.44 (+57.96%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.51 -0.14 (-2.15%)

As of 08/14/2026 08:00 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

DBV Technologies NASDAQ:DBVT

$14.02 -0.01 (-0.07%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.04 +0.02 (+0.14%)

As of 08/14/2026 04:20 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Kura Oncology NASDAQ:KURA

$10.86 +0.77 (+7.63%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$10.91 +0.05 (+0.45%)

As of 08/14/2026 07:34 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ANNX, KURA, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ANNX, KURA, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ANNX, KURA, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CAPR, ANNX, KURA, and DBVT Company Descriptions

Annexon NASDAQ:ANNX

Capricor Therapeutics NASDAQ:CAPR

DBV Technologies NASDAQ:DBVT

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ANNX, KURA, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ANNX, KURA, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ANNX, KURA, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CAPR, ANNX, KURA, and DBVT Company Descriptions

Annexon NASDAQ:ANNX

Capricor Therapeutics NASDAQ:CAPR

DBV Technologies NASDAQ:DBVT

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools